Example scenario, not a real patient
We wrote this walkthrough to explain the steps. The family is invented. It does not describe a real patient, doctor or hospital, and it is not a result we are reporting. The rules, dates and medical facts in it come from the sources listed at the end, checked on 17 October 2026.
Example scenario: a family in Dubai asks about a cell therapy given only at specialized centers
When the medicine is made from the patient's own cells, the family usually goes to the treatment, not the other way round.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
The situation
A family in Dubai has a 16-year-old daughter with synovial sarcoma, a rare soft-tissue cancer. It has spread even though she has had chemotherapy.
Her oncologist mentions Tecelra (afamitresgene autoleucel), a one-time therapy made from the patient's own T cells. The US FDA approved it on 1 August 2024. Since the June 2026 label update it covers adults and children 12 and older with synovial sarcoma that cannot be removed or has spread, after chemotherapy, who carry certain HLA-A*02 tissue types and whose tumor shows the MAGE-A4 protein on an FDA-approved or cleared test.
The family asks: is she eligible, can it be given in the UAE, and how long would they need to be away from home?
Why it is not simple
We did not find Tecelra in Abu Dhabi's Department of Health drug code list when we checked on 17 October 2026, and we could not check the federal Emirates Drug Establishment directory, so its UAE status is not confirmed.
More important, Tecelra is not a medicine that can simply be shipped to a local hospital. Each dose is made for one patient from her own cells. At launch in 2024 the company planned to offer it through designated treatment centers in the United States, so for most families the realistic route is treatment at a qualified center abroad.
What happens, step by step
- Eligibility tests come first.
Before anything else, two tests decide whether Tecelra is even possible: tissue typing for HLA-A*02, and a test of the tumor for the MAGE-A4 protein. The label says Tecelra must not be used in patients who carry HLA-A*02:05P.
Her oncologist arranges these tests and gathers her records: pathology, imaging and the chemotherapy she has had.
- Referral and center review.
The oncologist refers her to a qualified treatment center. The center reviews the records and decides whether she is eligible. The family confirms funding: personal funds, an insurer, or a government treatment-abroad decision.
- Collecting her cells.
At the center, her white blood cells are collected by leukapheresis, a process similar to giving blood. The cells are sent to be manufactured into her own dose.
In the clinical trial in the label, manufacturing or shipping failed for 7% of patients. When a second manufacture was tried, it succeeded in all 10 cases. Some patients need other cancer treatment while they wait; in the trial, 40% received this bridging therapy.
- Chemotherapy before the infusion.
The center confirms the finished dose has arrived before starting lymphodepleting chemotherapy. Fludarabine is given for 4 days and cyclophosphamide for 3 days, starting 7 days before the infusion.
- The infusion and the weeks after.
Tecelra is given as a single infusion. The label says patients are monitored daily at the healthcare facility for at least 7 days for cytokine release syndrome, must stay near a healthcare facility for at least 2 weeks, and should not drive for at least 2 weeks.
Tecelra has a boxed warning for cytokine release syndrome, which can be severe or life-threatening. Low blood counts can last for several weeks after the chemotherapy, so the center decides when it is safe to travel home.
Which time points are fixed
| Stage | Who sets the time | What the sources say |
|---|---|---|
| HLA and MAGE-A4 tests | Her oncologist and the testing laboratory | No fixed time |
| Center review and funding | The treatment center and the family | No fixed time |
| Cell collection to finished dose | The manufacturer | No fixed time in the label; 7% failure rate in the trial |
| Lymphodepleting chemotherapy | The center, following the label | Starts 7 days before the infusion |
| Daily monitoring after infusion | The center, following the label | At least 7 days |
| Staying near the center | The center, following the label | At least 2 weeks, longer if the center advises |
Regulators, manufacturers and hospitals set their own timelines, and most do not publish a fixed review time. We give you a written timeline estimate once we see the hospital file.
Documents usually needed
- A referral letter from the treating oncologist with the diagnosis and treatment history
- Pathology reports, and tumor tissue for the MAGE-A4 test if the center asks for it
- The HLA typing report
- Recent imaging and clinic notes, translated into English where needed
- Passports and travel documents for the patient and a parent
- A funding plan: personal funds, insurer approval, or a government treatment-abroad decision
What it may cost
Medicine price: quote on request. The treatment center's charges, travel and accommodation are separate and are set by the center and the family's own arrangements. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
What Reserve Meds does, and does not do
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. Reserve Meds can help the family organize records and translations, prepare questions for the treatment center, and keep everyone updated. If a hospital in the UAE ever becomes able to give Tecelra, we can explain the import route. We do not prescribe, and the treatment center decides eligibility.
Ask us about your own case
Tell us the medicine, the country, and how to reach you. We reply within one business day. On WhatsApp we usually reply the same day.
Message us on WhatsApp Already have a case? Sign in
Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
Sources
Checked on 17 October 2026. Regulator rules and lists change. Your hospital pharmacy confirms the current procedure before filing.
- FDA: TECELRA (afamitresgene autoleucel) product page and US prescribing information (revised June 2026)
- FDA: 2024 biological license application approvals (TECELRA, 1 Aug 2024)
- FDA: TECELRA US prescribing information (revised 6/2026): eligibility tests, lymphodepletion, monitoring, manufacturing failure rate
- Fierce Pharma: FDA signs off on Adaptimmune's Tecelra, 2 Aug 2024
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
Related
- Tecelra overview
- UAE country guide
- Named-patient access in the Gulf, explained
- All example scenarios
- Our editorial standards
- اقرأ هذه الصفحة بالعربية
This page is general information, not medical advice. Your own doctor decides what is right for you.